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Abstract: To investigate whether carbon-ion beam alone, or in combination with lapatinib, has a beneficial effect in 
targeting HER2-positive breast cancer stem-like cells (CSCs) compared to that of X-rays, human breast CSCs derived 
from BT474 and SKBR3 cell lines were treated with a carbon-ion beam or X-rays irradiation alone or in combination 
with lapatinib, and then cell viability, spheroid formation assays, apoptotic analyses, gene expression analysis of 
related genes, and immunofluorescent γ-H2AX foci assays were performed. Spheroid formation assays confirmed 
that ESA+/CD24- cells have CSC properties compared to ESA-/CD24+ cells. CSCs were more highly enriched after 
X-ray irradiation combined with lapatinib, whereas carbon-ion beam combined with lapatinib significantly decreased 
the proportion of CSCs. Carbon-ion beam combined with lapatinib significantly suppressed spheroid formation com-
pared to X-rays combined with lapatinib or carbon ion beam alone. Cell cycle analysis showed that carbon ion beam 
combined with lapatinib predominantly enhanced sub-G1 and G2/M arrested population compared to that of car-
bon-ion beam, X-ray treatments alone. Carbon-ion beam combined with lapatinib significantly enhanced apoptosis 
and carbon-ion beam alone dose-dependently increased autophagy-related expression of Beclin1 and in combina-
tion with lapatinib greatly enhanced ATG7 expression at protein levels. In addition, a large-sized γH2AX foci in CSCs 
were induced by carbon ion beam combined with lapatinib treatment in CSCs compared to cells receiving X-rays or 
carbon-ion beam alone. Altogether, combination of carbon-ion beam irradiation and lapatinib has a high potential 
to kill HER2-positive breast CSCs, causing severe irreparable DNA damage, enhanced autophagy, and apoptosis.
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Introduction
Breast cancer (BC) is the most frequently diag-
nosed cancer and is the leading cause of can-
cer-related deaths in worldwide [1]. BC is rap-
idly increasing in many Asian countries and 
has become the fifth-leading cause of cancer 
deaths in Japan [2-4]. BCs represent a group of 
highly heterogeneous lesions consisting of 
morphologically distinct subtypes with different 
molecular and biochemical signatures [5-7]. 
Tumors that overexpress the receptor tyrosine 
kinase HER2 (HER2-positive tumors) tend to 
be higher grade tumors that are more likely to 
spread and thus are more aggressive than 
other types of BCs [8]. Approximately 10~15% 
of women diagnosed with BC will have a HER2-
positive disease. HER2-positive type BCs can 
be treated with anti-HER2 drugs such as tras- 
tuzumab, and new studies shows that trastu-
zumab improves the long-term survival of 
patients with HER2-positive BCs [9, 10]. Al- 
though the clinical outcomes of patients with 
HER2-positive BC are much improved by trastu-
zumab treatment, these patients are more than 
twice as likely to develop a recurring cancer 
[11-13].
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Because BCs are highly heterogeneous both in 
their pathology and in their molecular profiles, 
the treatment of BCs should be designed 
according to their different subtypes in order 
to achieve desirable outcome [14-16]. Breast 
cancer stem-like cell (CSC) populations have 
recently been identified based on the cell mem-
brane markers CD44+/CD24- or ESA+/CD24- 
cells [17-19]. It has been demonstrated that 
CSCs are shown to be radioresistant owing to 
their high DNA repair capacity and upregulated 
survival pathways, which protect them from 
various cellular stresses, including radiation. It 
is therefore very important to develop novel 
therapeutic strategies that target CSCs in order 
to improve patient’s survival [20-22].
Carbon-ion beams have a well-localized ener- 
gy deposition, releasing enormous amount of 
energy in a well-defined range with insignificant 
scatter in surrounding tissues. As such, carbon-
ion beams can induce more complex DNA dam-
age and have been shown to be more effective-
ly in killing radioresistant cancer cells, with less 
cell-cycle and oxygen dependencies, compared 
to conventional radiation [23-25]. Recently, a 
phase I clinical trial for early stage BC treat-
ment using carbon-ion beam radiotherapy was 
started. However, one of critical problems was 
the elevated doses of radiation, especially with 
aggressive subtypes like HER2-positive tumors, 
used in carbon-ion radiotherapy, because of its 
side effects on skin, ribs, and lungs. Lapatinib 
is a very low molecular weight, dual inhibitor of 
the intracellular tyrosine kinase domain of 
HER1 (or EGFR) and HER2, and therefore has 
potential activity against brain metastases 
originating from HER2-positive BCs [26-29]. In 
this study, we reasoned that carbon-ion beam 
combined with molecular targeting drugs may 
reduce the doses of irradiation needed to effec-
tively destroy BC cells. The combination of lapa-
tinib and heavy ion radiotherapy may open new 
perspectives in the fight against this challeng-
ing BC subgroup which suffers from limited 
therapy options and poor prognosis.
Recently, we have reported that carbon-ion 
beam irradiation has a marked effect on colon 
and pancreatic CSCs [30, 31] and also shown 
that carbon ion beam combined with DNA dam-
aging drugs has increased efficacy in killing 
radioresistant CSCs [32-34]. Considering the 
fact that lapatinib has been reported to be 
effective in treating HER2-positive metastases 
[26-29], the present study examined the effects 
of carbon-ion beam irradiation alone or in 
combination with lapatinib on putative HER2-
positive breast CSCs survival, DNA repair, and 
expression changes of various cell death-relat-
ed genes compared to that of X-ray irradiation. 
To the best of our knowledge, this is the first 
study to show that heavy-ion radiation com-
bined with lapatinib has an advantage in target-
ing HER2-positive breast CSCs when compared 
to carbon-ion beam alone or conventional 
X-rays.
Materials and methods
Cell lines and reagents
Human HER2-positive breast cancer cell lines, 
BT474 and SKBR3 were purchased from 
American Type Culture Collection (Manassas, 
VA). Unsorted cells were cultured in Dulbecco’s 
Modified Eagle’s medium (DMEM) supplement-
ed with 10% heat-inactivated fetal bovine 
serum (FBS, Beit-Heamek, Israel), 100 unit/mL 
penicillin and 100 μg/mL streptomycin (Invitro- 
gen) at 37°C with 5% CO2-in-air. The medium 
was changed every other day. CSCs and non-
CSCs isolated from BT474 and SKBR3 cells 
were cultured with Cancer Stem Cell medium 
(Heidelberg. Germany). Lapatinib was purcha- 
sed from Sigma Japan. The lapatinib solutions 
were diluted in DMSO immediately before use. 
Antibodies used in the present study were as 
follows: mouse anti-human CD24-FITC (BD 
Pharmingen™ Cat No. 555427), mouse anti-
human CD326 (Miltenyi Biotec, Cat No. 130-
091-253), monoclonal anti-phospho-histone 
H2AX (Ser139) (γH2AX, abcam, ab26350), LC3 
(CST #4108), Beclin1 (CST #3738) and ATG7 
(CST #2631).
Spheroid formation assays
Spheroid formation ability assay for ESA+/
CD24- and ESA-/CD24+ cells sorted from 
BT474 and SKBR3 cells were performed as 
described previously [20]. In brief, 3000 cells 
per well were plated in a Low Cell Adhesion 
96-well plate (SUMILON, Sumitomo Bakelite, 
Tokyo, Japan) for 1-week and then the sphere 
area dimension was estimated. The data is pre-
sented as the average size using WinRoof 5.6 
software (Mitani Corporation, Tokyo, Japan) 
after 1-week incubation.
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Irradiation
Cells were irradiated with carbon-ion beams 
(accelerated by the HIMAC). Briefly, the initial 
energy of the carbon-ion beams was 290 
MeV/n, 50 KeV/μm, center of 6 cm Spread-Out 
Bragg Peak (SOBP). As a reference, cells were 
also irradiated with conventional 200 kVp X-ray 
(TITAN-320, GE Co., USA). 
Cell viability assay
For the analysis of cell viability, a CellTiter-Glo 
luminescent cell viability and trypan blue stain-
ing assays were used. The CellTiter-Glo® 
Luminescent Cell Viability Assay is a homoge-
neous method to determine the number of via-
ble cells in culture based on quantitation of 
the ATP present, which signals the presence of 
metabolically active cells. In brief, a single 
reagent (CellTiter-Glo® Reagent) directly added 
to cells which cultured in multiwell plate with 
serum-supplemented medium and estimated 
by GloMax® Discover System (Promega, Wis- 
consin, USA). Cell viability was also tested by 
trypan blue exclusion test, which based on the 
principle that live cells exclude trypan blue dye 
and do not stain, whereas dead or dying cells 
will be stained. In brief, dilute the cells by pre-
paring a 1:1 dilution of the cell suspension 
using 0.4% Trypan Blue solution and added to 
the Counting Slide Chamber and then estimat-
ed by using an Olympus Automated Cell Counter 
model R1 (Olympus, Tokyo, Japan).
Fluorescence-activated cell sorting (FACS) 
analysis
FACS analysis for the cells irradiated with X-rays 
or carbon ion beams was performed with BD 
FACS Aria (Becton Dickinson, San Jose, CA, 
USA) as described previously [23, 27]. In brief, 
the cells were prepared and labeled with con- 
jugated anti-human ESA-PE and CD24-FITC. 
Isotype matched immunoglobulin served as 
control. Cells were incubated for 20 min at 
each step and were washed with 2% FBS/PBS 
between steps. The percentage of ESA+, and 
CD24+ present was assessed after correction 
for the percentage of cells reactive with an iso-
type control.  
Apoptotic analysis
The apoptosis was analyzed using Annexin-V/PI 
doubling staining flow cytometry assay with 
Annexin V-FITC Apoptosis Detection Kits, 
according to the commercial procedure avail-
able (R&D Systems, Minneapolis, MN USA). 
Briefly, after 24 h of irradiation cells were har-
vested by trypsinization, washed in PBS and 
labeled fluorescently for detection of apoptotic 
and necrotic cells by adding 100 μL of binding 
buffer and 1 μL of Annexin V-FITC to each sam-
ple. Samples were mixed gently and incubated 
at room temperature in the dark for 15 min. 
Immediately before analysis by flow cytometry 
(BD FACSCalibur Flow Cytometry System), 1 μL 
of propidium iodide (PI, 1 mg/mL; Cedarlane 
Laboratories, Hornby, Ontario, Canada) were 
added to each sample. A minimum of 10,000 
cells within the gated region was analyzed. 
Cell cycle analysis
After harvesting and washing cells with phos-
phate-buffered saline (PBS), fix in ice-cold 70% 
ethanol (ethanol in distilled water) while vortex-
ing, then stained with propidium iodide (1 μg/
mL, Sigma) in the presence of RNase A accord-
ing to the manufacturer’s protocol, and then 
analyzed using a BD FACS Calibur flow cytome-
ter (BD Biosciences). A minimum of 10,000 
cells was counted for each sample, and data 
analysis was performed with CellQuest softwa- 
re.
Real time reverse transcription polymerase 
chain reaction (RT-PCR) analysis of various 
gene expression related to apoptosis and au-
tophagy 
RNA was purified using the Qiagen RNAeasy 
kit, including on-column DNAse treatment to 
remove genomic DNA. cDNA was prepared with 
the RT2 First Strand Kit (SABiosciences, 
Frederick, Maryland, USA). A PCR specific for 
apoptosis, autophagy related genes was per-
formed (RT2 SYBR Green/ROX qPCR Master 
Mix; SABiosciences) in 96-well microtiter plates 
on a LightCycler® 96 system (Roche, Basel, 
Switzerland). For data analysis, the ΔΔCt meth-
od was applied using the RT PCR software 
package and statistical analyses performed (n 
= 3). This package uses ΔΔ CT-based fold 
change calculations and the Student’s t-test to 
calculate two-tail, equal variance p-values. The 
fold changes were calculated using the equa-
tion 2-ΔΔCt. If fold change was greater than 1, the 
result was considered as fold-upregulation. If 
fold change was less than 1, the negative 
inverse of the result was considered as fold-
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downregulation [26, 27]. The primer sequences 
used in this study was shown as Table 1. 
GAPDH used as a housekeeping gene in this 
study.
Western blotting analysis
Cells were irradiated with carbon-ion beam 
alone or in combination with lapatinib and incu-
bated for 96 h. The cells were harvested and 
lysed with Denaturing lysis buffer (Minute Total 
Protein Extraction Kit, Invent Biotechnologies). 
The extracted proteins were separated by sodi-
um-polyacrylamide gel electrophoresis and 
transferred to nitrocellulose membranes. The 
membranes were blocked with 1% (v/v) non-fat 
dried milk in Tris-buffered saline with 0.05% 
Tween 20 and with the approciate antibodies. 
Primary antibodies were used at a 1:1000 dilu-
tion, and secondary antibodies were used at a 
1:5000 dilution. Immunoreactive protein bands 
were visualized by enhanced chemilumines-
cence (Amersham Biosciences) and scanned.
Visualizing autophagy by fluorescence micros-
copy 
The cells which cultured in chamber slide were 
stained with Cyto-ID according to the manufac-
turer’s protocol. In brief, cells were washed with 
PBS (supplemented with 5% FBS) and then 
mixed with Cyto-ID Dual Detection Reagent 
solution (Cyto-ID Green Detection Reagent and 
Hoechst 33342). The cells were then incubated 
at 37°C for 30 min (Cyto-ID) in the dark, then 
washed twice with PBS to remove the free dyes. 
The autophagic cells stained by Cyto-ID green 
fluorescence were observed using fluorescence 
microscope.
γH2AX immunofluorescence assay
γH2AX Immunofluorescence assay was per-
formed as described previously [26, 27]. In 
brief, cultured cells grown on plastic chamber 
slides (Lab-Tek. Nunc, USA) were fixed in 4% 
formaldehyde for 15 min at room temperature. 
Then the cells were permeabilized in 0.2% 
Triton X-100 and blocked with 10% goat serum, 
then incubated with mouse monoclonal anti-
phospho-histone H2AX (Ser139) (γH2AX) at 
37°C in PBS with 10% goat serum and washed 
with PBS. The cells were incubated with the 
Alexa 488 anti-rabbit secondary antibody at 
37°C in PBS with 10% goat serum and washed 
in PBS. Cover glasses were mounted in 
ProLong® Gold antifade reagent with DAPI 
(Invitrogen). Fluorescence images were cap-
tured using an Olympus DP70 fluorescence 
microscope for analysis. All treatment groups 
were then assessed for γH2AX foci via sequen-
tial imaging through each nucleus. A minimum 
of 100 cells in each treatment group were 
counted. Nuclear γH2AX foci size was estimat-
ed by ImageJ 1.45 software (NIH).
Statistical analysis
One-way analysis of variance (ANOVA) and 
Bonferroni multiple comparison tests were 
used when mean differences between the 
groups were evaluated by StatView software 
(SAS Institute, Inc., Cary, NC). For all compari-
sons, p values less than 0.05 were defined as 
significant.
Results
Cell viability after carbon ion beam or X-ray 
irradiation alone or in combination with lapa-
tinib
Morphological changes of BT474 cells as shown 
in Figure 1A, 24 h after carbon-ion beam com-
bined with lapatinib greatly destroyed the cells 




    Forward 5’-TGAACGGGAAGCTCACTGG-3’
    Reverse 5’-TCCACCACCCTGTTGCTGTA-3’
Bax
    Forward 5’-CAAACTGGTGCTCAAGGCC-3’
    Reverse 5’-GCACTCCCGCCACAAAGAT-3’
Bcl-2
    Forward 5’-ATGTGTGTGGAGAGCGTCAACC-3’
    Reverse 5’-TGAGCAGAGTCTTCAGAGACAGCC-3’
Caspase-3
    Forward 5’-TCATTATTCAGGCCTGCCGTGGTA-3’
    Reverse 5’-TGGATGAACCAGGAGCCATCCTTT-3’
LC3-II
    Forward 5’-GATGTCCGACTTATTCGAGAGC-3’
    Reverse 5’-TTGAGCTGTAAGCGCCTTCTA-3’
Beclin-1
    Forward 5’-AGCTGCCGTTATACTGTTCTG-3’
    Reverse 5’-ACTGCCTCCTGTGTCTTCAATCTT-3’
ATG-7
    Forward 5’-GCTG CTACTTC TGCAATGATGT-3’
    Reverse 5’-GCAAGCTCACTAGG CTGCAGAACC-3’
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compared to that of carbon-ion beam alone, 
X-ray irradiation alone or its combination treat-
ment with lapatinib. According to our and other 
previous reports, the relative biological effec-
tiveness (RBE) values are around 2.0, and in 
this study, we compared a 1 Gy dose of carbon-
ions with a 2 Gy of X-rays to evaluate their bio-
logical effects. At first, BT474 cell viability was 
performed using the CellTiter-Glo luminescent 
cell viability assay. As shown in Figure 1B, cell 
viability was significantly decreased after 1 Gy 
of carbon-ion beam, or X-rays alone, and it was 
predominantly decreased after 1 Gy of carbon-
ion beam in combined with 1 μM lapatinib com-
pared to 2 Gy of X-rays combined with lapatinib 
or with lapatinib alone. To further confirm the 
cell killing effects of carbon-ion beam alone or 
its combination with lapatinib, we also per-
formed Trypan Blue Staining assay. As shown in 
Figure 1C, cell viability was suppressed by car-
bon-ion beam irradiation alone dose-depend-
ently and it was significantly further decreased 
by carbon-ion beam irradiation combined with 
lapatinib. 
Changes in the proportion of ESA+/CD24- 
cells after carbon-ion beam or X-ray irradiation 
alone or in combination with lapatinib 
Percentage changes of cancer stem like ESA+/
CD24- CSCs 96 h after carbon-ion beam, or 
X-ray irradiation alone or in combination with 1 
μM of lapatinib were investigated by FACS anal-
ysis. As shown in Figure 2A, the proportion of 
ESA+/CD24- cells in BT474 cells was signifi-
cantly increased after 2 Gy of X-rays combined 
with lapatinib or with lapatinib alone, whereas 
1 Gy of carbon-ion beam combined with lapa-
tinib significantly decreased the proportion of 
ESA+/CD24- cells. Interestingly, the percentage 
of ESA+/CD24- cells in SKBR3 cells was signifi-
cantly increased when 2 Gy of X-rays combined 
with lapatinib was used, but no changes were 
observed with 2 Gy of X-rays alone or with 1 Gy 
of carbon-ion beam combined with lapatinib. 
However, the proportion of ESA+/CD24- cells 
was predominantly decreased with either 4 Gy 
of X-rays or 2 Gy of carbon-ion beam combined 
with lapatinib (Figure 2B).
Figure 1. A. Morphological changes of BT474 cells 24 
h after carbon-ion beam irradiation alone, X-ray irra-
diation alone or its combination treatment with lapa-
tinib. B. Cell viability analysis using the CellTiter-Glo 
luminescent cell viability assay. BT474 cell viability is 
shown 24 h after carbon-ion beam irradiation alone, 
or X-ray irradiation alone or in combination with of 
lapatinib (1 µM). *, P<0.01, compared to control. C. 
Cell viability analysis using the Trypan Blue Staining 
assay. BT474 cell viability is shown 96 h after differ-
ent doses of carbon-ion beam irradiation alone, or 
in combination with of lapatinib (1 µM). *, P<0.01, 
compared to control.
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Spheroid formation ability of ESA+/CD24- and 
ESA-/CD24+ cells after carbon-ion beam or 
X-ray irradiation alone or in combination with 
lapatinib
Under experimental condition with a stem cell 
medium, only cancer cells with self-renewal 
ability are expected to grow and maintain 
their spheroid morphology. Thus, spheroid for-
mation assays have been widely used to evalu-
ate cancer stem cell properties. To investigate 
the ability to form spheroid bodies, isolated 
ESA+/CD24-CSCs and non-CSC ESA-/CD24+ 
cells were cultured in 96-well round-bottomed 
Sumilon cell tight spheroid plates. After being 
in culture for 1 week, the ability of ESA+/CD24- 
cells to form spheroid bodies was significantly 
higher than that of ESA-/CD24+ cells (Figure 3). 
To examine the effects of lapatinib on radio- 
sensitization to X-rays and carbon ion beams, 
spheroid formation ability assays of cancer 
stem-like ESA+/CD24- cells and non-cancer 
stem-like ESA-/CD24+ cells after irradiation 
with an X-rays or carbon-ion beam alone or in 
combination with lapatinib were performed. As 
shown in Figure 3A, we found that the tumor 
spheroid formations of stem-like ESA+/CD24- 
cells isolated from SKBR3 cell line was signifi-
cantly reduced by carbon-ion beam irradiation, 
and with lapatinib alone, but not by X-ray irradi-
ation, and it was extremely decreased by car-
bon-ion beam combined with lapatinib. In con-
trast, no spheres were formed in non-stem-like 
ESA-/CD24+ cells after X-rays or carbon-ion 
beam, either alone or in combination with lapa-
tinib. We have also examined the spheroid for-
mation ability of ESA+/CD24- cells isolated 
from the BT474 cell line and found that carbon-
ion beam alone did not reduced spheroid size 
but carbon-ion beam combination with lapa-
tinib significantly reduced not only spheroid 
size and but also the numbers. In contrast, 
Figure 2. A. Percentage changes of ESA+/CD24- cells by FACS analysis 96 h after carbon-ion beam or X-ray irradia-
tion alone or in combination with 1 µM of lapatinib in BT474 cells. Lapatinib was added prior to irradiation and 
treated for 96 h. B. Percentage changes of ESA+/CD24- cells by FACS analysis 96 h after carbon-ion beam or X-ray 
irradiation alone or in combination with 1 µM of lapatinib in SKBR3 cells. Lapatinib was added prior to irradiation 
and treated for 96 h. *, P<0.01 compared to non-CSCs. All experiments were performed in triplicate (n = 3).
Figure 3. Spheroid formation of cancer stem-like cells (CSCs) (ESA+/CD24-) and non-CSCs (ESA-/CD24+) isolated 
from SKBR3 (A) and BT474 (B) cells. Cells were cultured for one week for spheroid formation ability analyses. *, 
P<0.01, #, P<0.05 compared to spheres formed from the Control. All experiments were performed in triplicate (n 
= 3).
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X-ray irradiation alone, lapanitib alone did not 
reduced the spheroid size and the numbers, 
even in combination with lapatinib (Figure 3B).
Apoptosis analyses after carbon-ion beam or 
X-ray irradiation alone or in combination with 
lapatinib
Induction of apoptosis in BT474 cells was ana-
lyzed using the Annexin V-FITC Apoptosis 
Detection kits 10 days after carbon-ion beam 
or X-ray irradiation alone or in combination with 
lapatinib. The data showed that there is no 
clear dose-dependent response with carbon-
ion beam irradiation, however, only 1 Gy was 
sufficient to significantly increase apoptosis 
(Figure 4A). In comparison, there is a clear 
dose-dependent response with X-ray irradia-
tion, but more than 4 Gy is needed to signifi-
cantly increase apoptosis (Figure 4B). Inter- 
estingly, carbon-ion beam in combination with 
lapatinib synergistically enhanced apoptosis, 
whereas no such action was observed using 
X-rays combined with lapatinib. 
Cell cycle analyses after carbon-ion beam or 
X-ray irradiation alone or in combination with 
lapatinib
Cell cycle analyses of BT474 cells 4 days after a 
carbon-ion beam, or X-rays alone or in combina-
tion with 1 μM of lapatinib were performed. 
Lapatinib was added prior to irradiation and 
constantly applied for 4 days, and then the cell 
cycle distribution (sub G1, G1, S and G2/M 
phase) was measured using an FACS Calibur. 
As shown in Figure 5, carbon-ion beam irradia-
tion combined with lapatinib was more effec-
tive in inhibiting cell cycle progression (sub-G1 
arrest) and inducing cell death (apoptosis/
necrosis) than X-rays alone or X-rays combined 
with lapatinib. We have also performed cell 
cycle analyses in SKBR3 cells and obtained the 
same results (data not shown).
γH2AX foci formation in ESA+/CD24- and 
ESA-/CD24+ cells after carbon-ion beam or 
X-rays alone or in combination with lapatinib
To examine the role of lapatinib radiosensitiza-
tion on DNA damage and repair in stem-like 
ESA+/CD24- cells, the γ-H2AX foci formation 
analysis was performed, which marks DNA dou-
ble-strand breaks (DSB). As shown in Figure 
6A, carbon-ion beam and X-rays significantly 
increased the number of γH2AX foci, with no 
observable differences between them, and this 
number was significantly increased further 
using carbon ion beam combined with lapa-
tinib. However, the size of foci (clustered DSB) 
was frequently found in cells treated by carbon-
ion beam combined with lapatinib compared to 
carbon-ion beam alone, X-rays alone, lapatinib 
alone, or X-rays combined with lapatinib (Figure 
6A). We also examined the nuclear γH2AX foci 
formed in non-stem like ESA-/CD24+ cells 24 h 
after a carbon-ion beam or X-ray irradiation 
alone or in combination with 1 μM of lapatinib. 
We found that many more numbers of γH2AX 
foci were present after carbon-ion beam treat-
ment alone compared to X-ray alone, and either 
carbon ion beam or X-ray irradiation combined 
with lapatinib enhanced γH2AX foci formation 
(Figure 6B).
Expression changes of various genes in CSCs 
after carbon-ion beam alone or X-rays alone 
or in combination with lapatinib measured by 
quantitative real-time RT PCR analysis
To quantitatively examine multiple gene expres-
sion changes in CSCs (ESA+/CD24-) and non-
CSCs (ESA-/CD24+) isolated from BT474 cells, 
quantitative real-time RT-PCR analysis was 
performed according to the manufacture’s pro-
tocol. The data shows that irradiation with a 
carbon-ion beam combined with a constant 
treatment of 1 μM of lapatinib for 72 h signifi-
cantly increased the expressions of apoptosis-
related caspase 3 but not Bax, and increased 
Bcl2 expression in both non-CSC and CSCs. 
Interestingly, expression of autophagy-related 
genes varied, LC3 was significantly increased 
only in non-CSCs, but Beclin1 expression was 
predominantly enhanced in both CSCs and 
non-CSCs after carbon-ion beam irradiation 
alone or in combination with lapatinib. In addi-
tion, no changes in ATG7 expression were found 
after treatment with carbon-ion beam alone, or 
X-rays alone or combined with lapatinib when 
compared to carbon-ion beam alone, or lapa-
tinib alone in both non-CSC and CSCs (Figure 
7A, 7B). We have examined above autophagy-
related genes at protein levels and found that 
expressions of ATG7 and Beclin1 and were 
increased in a dose-dependent manner by 
carbon-ion beam alone and only ATG7 expres-
sion was further enhanced by combination 
treatment of carbon-ion beam and lapatinib, 
whereas expression of Beclin1 was undetect-
able (Figure 7C). Furthermore, we investigated 
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Figure 4. Apoptosis analysis of BT474 cells 10 days after a carbon-ion beam irradiation alone or in combination with 1 µM of lapatinib using the FITC Annexin-V-PI 
detection kit. *, P<0.01, #, P<0.05 compared to control. All experiments were performed in triplicate (n = 3).
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autophagosomes using Cyto-ID Autophagy 
Detection Kit. The cells treated with autophagy 
inducer rapamycin which used as a positive 
control. We found that 24 h after carbon-ion 
beam irradiation alone effectively induced 
autophagy and in combination with lapatinib 
seems to induce more strongly (Figure 7D).
Discussion
Although the anti-proliferative and pro-apoptot-
ic effects of lapatinib have been reported [35, 
36], the molecular mechanism of radiosensiti-
zation and modes of cell death by lapatinib 
combined with high liner energy transfer (LET) 
carbon-ion beam on HER2-overexpressing 
breast cancer cells have not been elucidated. 
In this study, we found that the HER2 positive 
breast cancer cell viability was significantly 
decreased by using carbon-ion beam, or by 
lapatinib alone, and it was further decreased by 
using carbon-ion beam in combination with 
lapatinib when compared to X-ray irradiation 
alone, X-rays combined with lapatinib also 
reduced cell viability, but was less effective 
than using carbon-ion beam together with lapa-
tinib. This is partially consistent with previous 
reports showing that lapatinib inhibits cell 
growth, enhances antibody-dependent cellular 
cytotoxicity and potentiates radiation-induced 
cell death of HER2-overexpressing cancer cells 
[37-39]. 
In the present study, the percentages of cancer 
stem-like ESA+/CD24- cells (CSCs) in BT474 
cell line showed a tendency to increase after 
either 2 Gy of X-rays or 1 Gy of carbon-ion 
beam, and it was significantly increased after 2 
Gy of X-rays in combination with 1 μM of lapa-
tinib. In contrast, 1 Gy of carbon ion beam com-
bined with lapatinib significantly decreased the 
proportion of CSCs in BT474 cells. The propor-
tional changes of CSCs in SKBR3 cells were not 
affected by 2 Gy of X-rays or 1 Gy of carbon-ion 
Figure 5. Cell cycle analyses of BT474 cells 4 days after carbon-ion beam, or X-rays irradiation alone or in combina-
tion with 1 µM of lapatinib. Lapatinib was added 2 h prior to irradiation and continued for 4 days, and the cell-cycle 
distribution (sub G1, G1, S and G2/M phases) was measured by flow cytometry. Carbon-ion beam combined with 
lapatinib significantly inhibited cell-cycle progression (sub-G1 arrest) and induced cell death (apoptosis/necrosis). 
All experiments were performed in triplicate (n = 3), and the averages of the three separate experiments are shown.
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beam, or with 1 μM of lapatinib alone. However, 
it was significantly increased by 2 Gy of X-ray 
irradiation in combination with lapatinib but not 
1 Gy of carbon-ion beam in combination with 
lapatinib, whereas it was significantly decreased 
by 4 Gy of X-rays or 2 Gy of carbon-ion beam 
combined with lapatinib. This finding suggests 
that CSC proportions can be reduced when 
lapatinib is combined with slightly increasing 
doses of radiation. This is partially consistent 
with ours and other previous reports [30-34, 
38-40]. At first, to confirm the CSC properties 
of ESA+/CD24- cells, we sorted this population 
from SKBR3 cells and examined its spheroid 
formation capability compared to sorted non-
CSC ESA+/CD24- cells. The data showed that 
ESA+/CD24- cells have a significantly higher 
spheroid formation capability than ESA-/CD24+ 
cells, indicating that ESA+/CD24- cells have 
CSC properties. This is in line with previously 
reports that ESA+/CD24- is a marker for breast 
CSC [18, 33]. We also examined and confirmed 
that demonstrate that ESA+/CD24- cells have 
CSC properties compared to ESA-/CD24+ cells 
sorted from the BT474 cell line based on its 
high spheroid formation ability (data not 
shown). Furthermore, the data shows that 
spheroid formation of CSCs was significantly 
inhibited by ccarbon-ion beam, or by lapatinib 
alone, and it was extremely suppressed by car-
bon-ion beam combined with lapatinib when 
compared to X-rays alone or X-rays combined 
with lapatinib. This suggests that breast CSCs 
are significantly radiosensitized when carbon-
ion beam is combined with lapatinib. 
To determine apoptosis induction after long-
term treatments of carbon-ion beam, or X-ray 
irradiation alone or in combination with lapa-
tinib, we analyzed the apoptosis using the 
Annexin V-FITC Apoptosis Detection Kits 10 
days later. The data showed that carbon-ion 
Figure 6. A. Quantification and representative photos of nuclear γH2AX foci formation in CSCs (ESA+/CD24-) iso-
lated from BT474 cells 24 h after a carbon-ion beam, or X-ray irradiation alone or in combination with 1 µM of 
lapatinib. Quantification of nuclear γ-H2AX foci larger than 1.5 mm2 is also displayed. Lapatinib was added prior to 
irradiation and continued for 2 h. Data represents mean ± SD. *P<0.05 compared to control. B. Quantification and 
representative photos of nuclear γH2AX foci formation in non-CSCs (ESA-/CD24+) isolated from BT474 cells 24 h 
after carbon-ion beam, X-ray irradiation alone or in combination with 1 µM of lapatinib. Lapatinib was added 2 h 
prior to irradiation and continued for 24 h. Data represent mean ± SD. *P<0.05 compared to control. All experiments 
were performed in triplicate (n = 3).
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Figure 7. Quantitative real time RT-PCR analysis of apoptosis (A) and autophagy-related (B) genes in CSCs and non-
CSCs isolated from BT474 cells 96 h after a carbon-ion beam, or X-ray irradiation alone or in combination with 1 µM 
of lapatinib. Lapatinib was added 2 h prior to irradiation and continued for 96 h. *, P<0.01, compared to control. All 
experiments were performed in triplicate (n = 3). (C) Western blotting analysis of ATG7 and Beclin1 in BT474 cells 
96 h after a carbon-ion beam alone or lapatinib alone, or in combination with lapatinib. (D) Visualizing autophagy 
by fluorescence microscopy. The autophagic cells stained by Cyto-ID dual detection reagent solution (Cyto-ID Green 
Detection Reagent and Hoechst 33342) and were observed using fluorescence microscope.
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beam irradiation alone can increase apoptosis, 
although there is no dose-related response, 
whereas X-ray irradiation alone increased 
apoptosis in a dose-dependent manner. In- 
terestingly, carbon ion beam in combination 
with lapatinib dramatically enhanced apoptosis 
compared to carbon-ion beam alone, lapatinib 
alone, X-rays alone or in combination with lapa-
tinib. The cell cycle distribution of BT474 and 
SKBR3 cells 4 days after a carbon-ion beam, or 
X-ray irradiation alone or in combination with 1 
μM of lapatinib was analyzed by flow cytometry. 
Carbon-ion beam combined with lapatinib more 
significantly inhibited cell cycle progression 
(sub-G1 arrest) and induced cell death (apopto-
sis/necrosis) compared to carbon-ion beam 
alone, X-rays alone or X-rays combined with 
lapatinib in both BT474 and SKBR3 (data not 
shown) cells. This is in line with previous reports 
showing that lapatinib induces apoptosis in 
various cancer cells [35, 36].
There is increasing evidence indicating that 
high LET particle irradiation can induce com-
plex DNA damage such as clustered DNA 
lesions [41-44]. In this study, the number of 
double strand breaks (DSBs) visualized by 
γH2AX foci formation in non-CSCs and CSCs 
was significantly increased by carbon-ion be- 
am, X-ray irradiation alone, or in combination 
with lapatinib with no significant difference 
among the treatments. However, significantly 
larger-sized γH2AX foci were only induced by 
carbon-ion beam irradiation, and carbon-ion 
beam combined with lapatinib induced more 
large-sized γH2AX foci, suggesting that a higher 
complexity of clustered DSB was induced by 
carbon ion beam in combination with lapatinib. 
These results reveal that the greater complexi-
ty of DSBs induced by carbon-ion beam com-
bined with a molecular target drug which po- 
tentially leads to increased mutagenicity and 
decreased reparability of the damaged site [43, 
44]. Taken together, our results are the first to 
show that carbon-ion beam in combination with 
lapatinib synergistically enhanced cell killing of 
HER2-positive CSCs. This is partially consistent 
with previous reports that HER2 is preferential-
ly expressed in the CSC population, and HER2 
targeting drug trastuzumab found to effectively 
reduced tumor sphere formation and CSC 
markers [10, 40].
A number of studies showed that CSC subpopu-
lations are shown to be radioresistant com-
pared to non-CSC subpopulations and cross-
talk between autophagy signaling and apopto-
sis signaling was considered as one of this 
resistant mechanisms [41]. In the present 
study, we found that after treatment with car-
bon-ion beam combined with lapatinib for 
radioresistant CSCs, apoptosis-related gene 
expression of caspase 3 but not Bax, and 
autophagy-related genes like LC3 and Beclin1 
showed significant enhancements compared to 
that of carbon ion beam, X-ray alone or X-ray 
combined with lapatinib, suggesting that car-
bon-ion beam combined with lapatinib may 
have more power to induce multiple cell death. 
Altogether, carbon-ion beam combined with 
lapatinib appear to show enhanced effects in 
inducing apoptosis and autophagy related gene 
expression at the mRNA levels in vitro in the 
disruption of HER2-positive breast CSCs. Cyto-
ID autophagy flux immunofluorescence analy-
sis indicated that 24 h after carbon-ion beam 
irradiation alone effectively induced autophagy 
and combination treatment with lapatinib 
seems to be induced autophagy more strongly. 
Furthermore, western blot data showed that 
carbon-ion beam dose-dependently increased 
expression of ATG7 and Beclin1, however car-
bon-ion beam in combination with lapatinib 
only enhanced ATG7 expression, whereas ex- 
pression of Beclin1 was lost. We speculated 
that relatively long-term treatment (96 h) with 
lapatinib and/or in addition with carbon-ion 
beam may strongly killed most of tumor cells 
and degraded some proteins. It has been 
reported that lapatinib radiosensitized BCs are 
accompanied with apoptosis and autophagy 
[38-40], and lapatinib induces autophagic cell 
death and combined treatment with rapamycin, 
a autophagy activator, or with radiation further 
increased autophagy in HER2 positive breast 
cancer cells [45-52]. It has also demonstrated 
that Tat-Beclin1 peptide inhibits HER2 positive 
human breast cancer xenograft with robust 
autophagy induction [53]. Based on above lit-
erature and our present findings, it is implying 
that carbon ion beam in combination with lapa-
tinib may enhance cell death via autophagy 
induction [54]. However, the deep molecular 
mechanisms of carbon ion beam irradiation 
alone or lapatinib combination treatment-
induced apoptosis, autophagy and their inter-
action need to be further studied. In addition, it 
has been demonstrated that overexpression of 
the HER2 gene results in the formation of a 
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ligand-independent HER2 homodimer and initi-
ate downstream signaling cascades, such as 
the phosphoinositide 3-kinase (PI3K) and mito-
gen-activated protein kinase (MAPK) pathways, 
which regulate cell proliferation and survival 
[55]. We plan to further investigate the effects 
of carbon-ion beam irradiation in combination 
with lapatinib on these of signaling pathways in 
the near future.
In summary, relatively low doses of carbon-ion 
beam combined with lapatinib have promising 
advantages in targeting putative HER2-positive 
breast CSCs by inducing complex DNA damage, 
increased apoptosis, autophagy, and subse-
quent cell death then by using carbon-ion beam 
alone.
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